Mark Dixon

Mark Dixon

Roche - Basel / Switzerland
Medical and Health Sciences / Hematology
AD Scientific Index ID: 4386737
-
person_outline Mark Dixon's MOST POPULAR ARTICLES
1-) Venetoclax and obinutuzumab in patients with CLL and coexisting conditionsK Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ...New England Journal of Medicine 380 (23), 2225-2236, 20196142019
2-) Glofitamab for relapsed or refractory diffuse large B-cell lymphomaMJ Dickinson, C Carlo-Stella, F Morschhauser, E Bachy, P Corradini, ...New England Journal of Medicine 387 (24), 2220-2231, 20221502022
3-) Venetoclax and obinutuzumab in chronic lymphocytic leukemiaK Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ...Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 20171322017
4-) Bitopertin in negative symptoms of schizophrenia—results from the phase III FlashLyte and DayLyte studiesD Bugarski-Kirola, T Blaettler, C Arango, WW Fleischhacker, G Garibaldi, ...Biological psychiatry 82 (1), 8-16, 20171272017
5-) Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trialA Davies, F Merli, B Mihaljević, S Mercadal, N Siritanaratkul, ...The Lancet Haematology 4 (6), e272-e282, 20171052017